Is Organon & Co. (OGN) a Buy, Sell, or Hold?
NYSE : OGN
Organon & Co.
$13.57 USD
$0.01 (0.11%)
- Volume
- 902.82K
- Average Volume
- 6.44M
- Market Capitalization
- $3.56B
- P/E Ratio
- 17.18
- Dividend Yield
- 0.59%
- Price Target
- $12.00
- Year High
- $13.60
- Year Low
- $5.69
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.09
- Current Ratio
- $1.95
Company Overview
NYSE
Joseph T. Morrissey Jr.
Drug Manufacturers - General
Healthcare
OGN
10000
US
USD
Liquidity Metrics
8.50
1.95
1.44
0.43
0.09
Sales & Valuation
$6.22B
0.58
3.54
7.16
1.90
Profitability
$0.72
$187M
3.41%
8.01%
23.44%
1.59%
P/E Metrics
17.18
-0.24
-0.24
Analyst Price Target & Rating
$12.00
$14.00
$8.00
3/5
9 Analysts
13.08%
Financial Health Scores
1.14
7/9
$2.5B
$13.18B
$12.17B
$991M
Key Metrics (TTM)
$10.98B
2.40
8.21
1.95
23.44%
4.73%
5.87%
13.98%
$8.28
170 days
Company Executives
| Name | Title |
|---|---|
| Juan Camilo Arjona Ferreira | Executive Vice President, Head of Research & Development and Chief Medical Officer |
| Daniel Karp | Chief Strategy Officer & Head of Corporate Development |
| Joseph T. Morrissey Jr. | Chief Executive Officer |
| Kirke Weaver | Executive Vice President, General Counsel & Corporate Secretary |
| Matthew Walsh | Executive Vice President & Chief Financial Officer |
| Carrie Smith Cox | Executive Chair of the Board |
| Rachel A. Stahler | Executive VP, Chief Information Officer and Chief Digital & Growth Officer |
| Aaron Falcione | Executive Vice President & Chief Human Resources Officer |
| Vittorio Nisita | Executive Vice President & Head of Enterprise Services and Solutions |
| Jennifer Halchak | Head of Investor Relations |
Poll Results
No votes yet today — be the first to share your view!
About Organon & Co. (NYSE:OGN) Stock
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages s ... easonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics
2026-07-31 12:01:13
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Organon (OGN) Lags Q2 Earnings Estimates
2026-07-31 10:46:12
Organon (OGN) came out with quarterly earnings of $0.85 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $1 per share a year ago.
Organon Announces Quarterly Dividend
2026-07-31 08:30:00
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company's Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on September 10, 2026, to stockholders of record at the close of business on August 14, 2026. About Organon Organon (NYSE: OGN) is a global h.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
2026-07-28 10:01:21
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Orogen Royalties Announces Project, Partner and Royalty Update
2026-07-27 07:30:00
VANCOUVER, BC / ACCESS Newswire / July 27, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties for the first half of 2026 and forecast for the remainder of the year. Highlights Approximately 44,000 metres of partner-funded drilling completed or underway on seven exploration stage projects where Orogen holds various royalty interests Over 7,000 metres of conversion drilling completed at Ermitano's Navidad/Winter deposit, where Orogen holds a cash-flowing 2% net smelter return ("NSR") royalty Received $1.72 million from the sale of projects and payments from exploration partners year to date Two new royalties created from project sales New pipeline of projects generated from partner-funded gold exploration in Nevada and Utah, and from Orogen's internally funded programs Additional six drill programs with 25,000 metres of drilling estimated in H2-2026 Paddy Nicol, CEO of Orogen, commented, "Orogen's strategy is built on a scalable business model of profitably generating highly prospective exploration stage mineral projects and advancing them through strategic partnerships, while retaining royalties.
2026-07-24 08:00:00
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Presents VTAMA (tapinarof) cream, 1% Analysis of Phase3 Pooled Data Showing Early Consistent Improvements in Eczema Patients Across Age Groups.
Organon & Co. Shareholders Clear Sun Pharma Merger Deal
2026-07-23 11:07:30
Shareholders of Organon & Co. NYSE: OGN approved the company's proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to preliminary voting results announced during the meeting.
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
2026-07-16 07:30:00
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the second quarter 2026, which will.
Frequently Asked Questions
-
What is the current Organon & Co. (OGN) stock price?
-
Organon & Co.(NYSE:OGN) stock price is $13.57 in the last trading session. During the trading session, OGN stock reached the peak price of $13.6 while $5.69 was the lowest point it dropped to. The percentage change in OGN stock occurred in the recent session was 0.11% while the dollar amount for the price change in OGN stock was $0.01.
-
OGN's industry and sector of operation?
-
The NYSE listed OGN is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of OGN?
-
Juan Camilo Arjona Ferreira | Executive Vice President, Head of Research & Development and Chief Medical Officer
Daniel Karp | Chief Strategy Officer & Head of Corporate Development
Joseph T. Morrissey Jr. | Chief Executive Officer
Kirke Weaver | Executive Vice President, General Counsel & Corporate Secretary
Matthew Walsh | Executive Vice President & Chief Financial Officer -
How many employees does OGN have?
-
Number of OGN employees currently stands at 10000. OGN operates from 30 Hudson Street, Jersey City, NJ 07302, US.
-
Link for OGN official website?
-
Official Website of OGN is: https://www.organon.com
-
How do I contact OGN?
-
OGN could be contacted at phone #551 430 6000 and can also be accessed through its website. OGN operates from 30 Hudson Street, Jersey City, NJ 07302, US.
-
How many shares of OGN are traded daily?
-
The average number of OGN shares traded daily for last 3 months was 6.44M.
-
What is the market cap of OGN currently?
-
The market value of OGN currently stands at $3.56B with its latest stock price at $13.57